CA2600004A1 - Spiro-heterocyclic chromans, thiochromans and dihydroquinolines - Google Patents

Spiro-heterocyclic chromans, thiochromans and dihydroquinolines Download PDF

Info

Publication number
CA2600004A1
CA2600004A1 CA002600004A CA2600004A CA2600004A1 CA 2600004 A1 CA2600004 A1 CA 2600004A1 CA 002600004 A CA002600004 A CA 002600004A CA 2600004 A CA2600004 A CA 2600004A CA 2600004 A1 CA2600004 A1 CA 2600004A1
Authority
CA
Canada
Prior art keywords
optionally substituted
compound
ring
alkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002600004A
Other languages
English (en)
French (fr)
Inventor
Danie T.W. Chu
Donald R. James
Bing Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2600004A1 publication Critical patent/CA2600004A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002600004A 2005-02-25 2005-12-09 Spiro-heterocyclic chromans, thiochromans and dihydroquinolines Abandoned CA2600004A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US65674805P 2005-02-25 2005-02-25
US65671105P 2005-02-25 2005-02-25
US60/656,711 2005-02-25
US60/656,748 2005-02-25
PCT/US2005/044713 WO2006093548A1 (en) 2005-02-25 2005-12-09 Spiro-heterocyclic chromans, thiochromans and dihydroquinolines

Publications (1)

Publication Number Publication Date
CA2600004A1 true CA2600004A1 (en) 2006-09-08

Family

ID=36941473

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002600004A Abandoned CA2600004A1 (en) 2005-02-25 2005-12-09 Spiro-heterocyclic chromans, thiochromans and dihydroquinolines

Country Status (8)

Country Link
US (1) US20080207588A1 (https=)
EP (1) EP1856079A4 (https=)
JP (1) JP2008531559A (https=)
AU (1) AU2005328328A1 (https=)
BR (1) BRPI0520097A2 (https=)
CA (1) CA2600004A1 (https=)
MX (1) MX2007010328A (https=)
WO (1) WO2006093548A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005316739A1 (en) 2004-12-13 2006-06-22 Galileo Pharmaceuticals, Inc. Spiro derivatives as lipoxygenase inhibitors
CA2924141C (en) 2013-08-22 2022-06-07 The General Hospital Corporation 5-amino 4-cyano substituted oxazole and thiazole derivatives as inhibitors of human 12/15-lipoxygenase
CN110627770A (zh) 2013-11-18 2019-12-31 福马疗法公司 作为bet溴域抑制剂的四氢喹啉组成物
RU2720237C2 (ru) 2013-11-18 2020-04-28 Форма Терапеутикс, Инк. Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1261835A (en) 1984-08-20 1989-09-26 Masaaki Toda (fused) benz(thio)amides
GB8626344D0 (en) 1986-11-04 1986-12-03 Zyma Sa Bicyclic compounds
US5059609A (en) 1987-10-19 1991-10-22 Pfizer Inc. Substituted tetralins, chromans and related compounds in the treatment of asthma, arthritis and related diseases
US4950684A (en) 1988-05-20 1990-08-21 G. D. Searle & Co. 2,2-di-substituted benzopyran leukotriene-D4 antagonists
US5015661A (en) 1988-08-09 1991-05-14 Hoffmann-La Roche Inc. Chromanes and their pharmaceutical compositions and methods
US5250547A (en) * 1991-08-29 1993-10-05 Syntex (U.S.A.) Inc. Benzopyran derivatives
SG48108A1 (en) 1991-11-22 1998-04-17 Lipogenenics Inc Tocotrienols and tocotrienol-like compounds and methods for their use
FR2695387B1 (fr) 1992-09-09 1994-10-21 Adir Nouveaux composés benzopyraniques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US5686389A (en) * 1994-04-13 1997-11-11 City Of Hope Growth inhibition of Erwinia amylovora
MX9702734A (es) 1994-10-13 1997-06-28 Pfizer Benzopirano y compuestos benzocondensados, su preparacion y su uso como antagonistas de leucotrieno b4 (ltb4).
AU696890B2 (en) 1994-10-13 1998-09-24 Pfizer Inc. Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene B4 (LTB4) antagonists
US5925673A (en) 1994-12-23 1999-07-20 Alcon Laboratories, Inc. Benzofurans and benzopyrans as cytoprotective agents
TW472051B (en) * 1997-05-23 2002-01-11 Chugai Pharmaceutical Co Ltd 2,3-dihydrobenzofuran derivatives
AU2005316739A1 (en) * 2004-12-13 2006-06-22 Galileo Pharmaceuticals, Inc. Spiro derivatives as lipoxygenase inhibitors
CA2599352A1 (en) * 2005-02-25 2006-09-08 Eli Lilly And Company Novel lipoxygenase inhibitors

Also Published As

Publication number Publication date
EP1856079A4 (en) 2008-12-31
EP1856079A1 (en) 2007-11-21
AU2005328328A1 (en) 2006-09-08
JP2008531559A (ja) 2008-08-14
MX2007010328A (es) 2008-03-13
US20080207588A1 (en) 2008-08-28
WO2006093548A1 (en) 2006-09-08
BRPI0520097A2 (pt) 2009-08-25

Similar Documents

Publication Publication Date Title
US7576094B2 (en) Spiro derivatives as lipoxygenase inhibitors
CA2583084C (en) 7,8-bicycloalkyl-chroman derivatives
CA2599352A1 (en) Novel lipoxygenase inhibitors
CA2352786C (en) Benzofuran derivatives, process for the preparation of the same and uses thereof
JP6622824B2 (ja) キヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法
TWI501960B (zh) 新穎吡喃酮-吲哚衍生物及其製備方法
JP2009545594A (ja) 改善された効能、安定性および安全性を有する疑似塩基ベンゾ［ｃ］フェナントリジン
WO2005027900A1 (en) Benzofuran derivatives
US5405864A (en) Chemotherapeutic maleimides
US10471054B2 (en) CDK1 inhibitors of acetyl chrysin mannich base derivatives, synthesis and use thereof
JPH08820B2 (ja) 新規のベンゾピラン化合物、その製造法、およびそれらを含む製薬組成物
JP2005518446A (ja) 過剰増殖性障害の処置に有用な縮合三環式複素環
US7528164B2 (en) Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
CA2600004A1 (en) Spiro-heterocyclic chromans, thiochromans and dihydroquinolines
CN109485691B (zh) 丹参酮类化合物及其用于治疗血管瘤的用途
JP2011529855A (ja) Ｔｒｐｖ３モジュレーターとしてのクロマン誘導体
DE68916685T2 (de) Mevalonolactone vom Typ Pyrazolopyridin.
AU2002353088A1 (en) Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
WO2024027845A1 (zh) 双四氢呋喃类化合物作为α-突触核蛋白聚集体形成抑制剂的用途、包含其的药物组合物
CN101163687A (zh) 螺-杂环苯并二氢吡喃、二氢苯并噻喃和二氢喹啉类化合物
KR102789906B9 (ko) 신규 피리미딘 유도체
JP2021020966A (ja) トコトリエノール誘導体、医薬組成物および５−リポキシゲナーゼ関連疾患における使用方法

Legal Events

Date Code Title Description
FZDE Discontinued